New Delhi, Jan. 29 -- Mumbai: Private equity firm InvAscent is writing significantly larger cheques in pharma-its core focus-as rising regulatory and manufacturing costs have pushed companies to raise more capital.

"Our ticket sizes in pharma have increased. We now participate in $80 million-$100 million deals along with our LPs (limited partners), where we roughly do a 50-50 split. Earlier, we engaged only in $30 million-$50 million transactions," founder and chairman Hari Buggana told Mint in an interview.

"It costs a lot more today to build a new facility to comply with the regulations, so companies naturally need to raise a lot more money."

The firm is also widening its investment lens to sub-segments such as health-tech. "Another ...